Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
PUBLIC HEALTH INSTITUTE (PHI)
Funding Organization
Temporal Graph
Map of Science
Research
Research
Awards Grant
A Phase 1, Open-Label, Dose-escalation trial of CD33xCD3 Bispecific Antibody in Pediatric patients with Relapsed of Refractory Acute Myeloid Leukemia - COG ADVL 2111
An Open-Label, Multi-Center Phase 1/2 study of Surufatinib in Combination with Gemcitabine in Pediatric Patients with Recurrent or Refractory Solid Tumors COG ADVL2121
COG Nursing Committee
COG Scientific Council
Cancer Care Delivery Study Chair
Children's Oncology Group NCTN Network Group Operations
Children's Oncology Group NCTN Network Group Operations
Children's Oncology Group NCTN Network Group Operations
Improving the Reach and Effectiveness of STD Prevention, Screening, and Treatment Services in Local Public Health Systems
Long-term Follow-up Center to Facilitate Survivorship Research within COG
NIH National Clinical Trials Network (NCTN) Grant (2U10CA180886) Successor to NIH National Clinical Trials Network (NCTN Grant (U10CA180886)
PEPN2111- A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma,
Per Case Reimbursement (PCR)- NIH National Clinical Trails Network (NCTN) Grant (U10CA180886) -PHI/COG
Workload Intensity NIH Nationl Clinical Trials Network (NCTN) Grant (U10DA180886) - PHI/COG
